etodolac (Lodine)
Jump to navigation
Jump to search
Introduction
Tradename Lodine.
Indications
- temporary relief of minor aches, pains, fever & inflammation
- osteoarthritis, bursitis,
- not as effective as other NSAIDs for rheumatoid arthritis
Dosage
200-400 mg PO TID/QID, max 1200 mg/day
Tabs: 200, 300, 400 mg.
Pharmacokinetics
- well absorbed, onset of action 30 min-1 hour
- volume of distribution L/kg
- highly protein bound
- elimination 1/2life is about 7 hours
elimination via liver
1/2life = 3.3-11.3 hours
Adverse effects
- GI distress
- GI bleeding
- nausea
- headache
- nephrotoxicity (by analogy to celecoxib & rofecoxib)
Drug interactions
- corticosteroids
- increased clearance of salicylates
- in combination increase renal & GI toxicity
- etodolac may decrease antihypertensive effects of ACE inhibitors
- in combination with warfarin may increase bleeding time
- etodolac may increase methotrexate levels & toxicity
- drug interaction(s) of cholinesterase inhibitors with NSAIDs
- drug interaction(s) of lithium carbonate with NSAIDs
- drug interaction(s) of NSAIDs with oral contraceptive
- drug interaction(s) of NSAIDs with SSRIs
- drug interaction(s) of NSAIDs with antidepressants
- drug interaction(s) of aspirin with NSAIDs
- drug interaction(s) of apixaban with NSAIDs
- drug interaction(s) of warfarin with NSAIDs
- drug interaction(s) of NSAIDs with beta blockers
- drug interaction(s) of NSAIDs with ARBs
- drug interaction(s) of NSAIDs with aldosterone antagonis
- drug interaction(s) of NSAIDs with glucocorticoid
- drug interaction(s) of NSAIDs, diuretics & angiotensin II receptor antagonists
- drug interaction(s) of NSAIDs, diuretics & ACE inhibitors
- drug interaction(s) of NSAIDs with ACE inhibitors
- drug interaction(s) of NSAIDs & antihypertensives
- drug interaction(s) of NSAIDs & loop diuretics
- drug interaction(s) of NSAIDs & aspirin
Mechanism of action
- non known, but presumed to inhibit cyclooxygenase
- analgesic, antipyretic & anti-inflammatory
More general terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 2000
- ↑ 4.0 4.1 Prescriber's Letter 12(3): 2005
- ↑ Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001